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1. Introduction 
Atherosclerosis and its consequences contribute to more than 50% of mortality in Europe, 
the United States of America and many developed or developing countries (Schafers et al., 
2010). The main pathologic substrate in atherosclerosis is the atherosclerotic lesion. The 
classical high-risk plaque is characterized by a large lipid core, a thin fibrous cap and many 
macrophages in the shoulder regions of the plaque (Falk et al., 1995; Stary et al., 1995). 
Rupture of the fibrous cap or, more subtle, erosion leads to exposure of the thrombogenic 
sub-endothelial matrix to blood leading to thrombus formation. Recurrent thrombosis or 
major atherothrombosis may lead to an acute cardiovascular event via sub(total) occlusion 
of the vessel of interest. Macrophages are the key mediators of plaque inflammation and 
progression (Lusis, 2000; Ross, 1999). Inflammatory activity can be evaluated at the cellular 
(macrophages and neutrophils) or sub-cellular (secreted enzymes, membrane-bound 
proteins) level. Sensitive and specific biomarkers of plaque inflammation and instability are 
highly desired for more accurate definition of high-risk plaques in high risk patient 
populations. At present, serologic markers do not accomplish this need sufficiently. 
Therefore, there is a need for noninvasive imaging techniques for identification and 
quantification of local plaque biomarkers, which can direct interventional cardiologists and 
vascular surgeons to diseased sites and can monitor therapeutic response.  
2. Atherosclerosis 
Atherosclerosis is characterized by various more or less orderly processes taking place 
during the development from a fatty streak to a rupture-prone or ruptured plaque (Ross, 
1999). Several morphological stages of plaque development related to risk of rupture were 
described by the American Heart Association (Stary et al., 1995). However, recently other 
plaques than the classical vulnerable plaque with a large lipid core and thin fibrous cap 
were also recognized as high-risk plaque, like highly calcified and obstructive plaques 
(Naghavi et al., 2003a, 2003b). During the process of atherogenesis, inflammation aggravates 
endothelial dysfunction and vice versa. First, low density lipoproteins are deposited in the 
subintima, where rare neutrophils and macrophages produce myeloperoxidase. This  
leads to generation of tyrosyl radicals and aldehydes resulting in oxidation of LDL. 
Oxidized LDL (ox-LDL) irritates endothelial cells which become dysfunctional, leading to 
inflammatory cell migration and activation. Macrophage activation leads to release of 
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matrix metalloproteinases, cathepsins and other matrix degrading enzymes. Activated 
macrophages also release factors that eventually cause apoptosis of smooth muscle cells, 
endothelial cells and macrophages themselves. Fibrous cap thinning, lipid core growth, 
formation of fragile intra-plaque neovasculature, intra-plaque hemorrhage and finally 
fibrous cap rupture may be the result of these processes. Fibrous cap rupture leads to 
exposure of the tissue under the broken endothelial barrier to the blood stream which 
activates coagulation. Subsequent formation of a thrombus may cause an acute thrombotic 
event (Libby, 2002; Lusis, 2000; Ross, 1999) .  
All these processes can serve as the target of molecular imaging techniques, at the cellular or 
subcellular/molecular level. The next section describes an overview of the available 
methods for in vivo molecular imaging of atherosclerosis. 
3. Molecular imaging techniques for atherosclerosis 
Various noninvasive imaging techniques are available for evaluation of the levels of the 
above inflammation-related cells, proteins or enzymes. Fluorescence imaging (FI), 
ultrasound (US), computed tomography (CT), positron emission tomography (PET), single-
photon-emission computed tomography (SPECT) and magnetic resonance imaging (MRI) 
are all imaging modalities with in vivo applicability that could play a role in molecular 
imaging of plaque inflammation (I.Y. Chen & Wu, 2011).  
Because light attenuation by tissue is wavelength dependent, fluorescent proteins with more 
red-shifted emission wavelength have been developed to maximize FI sensitivity and 
specificity. The advent of quantum dot technology alleviates the problems associated with 
protein-based optical reporters, e.g. photobleaching, low quantum yield, low absorbance 
and broad emission band. However, because of the limited imaging depth an intravascular 
catheter is needed for clinical application (Calfon et al., 2010). Further, cytotoxicity of 
quantum dots needs to be addressed and a second imaging modality (MRI or CT) is needed 
for anatomic colocalization before FI with quantum dots may be clinically implemented (Iga 
et al., 2007).  
Ultrasound with targeted micro-bubbles is restricted to the endothelial molecular targets, 
because the size of the bubbles (~1-10 µm) precludes their extravasation (I.Y. Chen & Wu, 
2011). Other disadvantages of US include the high degree of operator dependency, low 
micro-bubble adhesion efficiency and poor ability to image past bony structures.  
Recently, an iodinated CT contrast agent was used for imaging of macrophage activity in 
atherosclerotic plaques (Hyafil et al., 2007). The unknown toxicity of the high concentrations 
of organometallics needed for effective imaging, limited differentiation between diverse soft 
plaque constituents and the high radiation exposure limit clinical application of molecular 
CT.  
After intravenous administration of the PET-tracer F-18-fluorodeoxyglucose, metabolically 
active cells may take up this tracer. This has been shown useful for PET/CT imaging of 
atherosclerotic plaque inflammation in carotid, iliac and femoral arteries of patients (Rudd 
et al., 2007). PET and SPECT are techniques allowing imaging of disease processes in vivo 
with nanomolar/picomolar sensitivity (Massoud & Ghambir, 2003). SPECT was applied for 
imaging of plaque apoptosis in an atherosclerotic rabbit model (Kolodgie et al., 2003), and 
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lipid-rich lesions of mice and rabbits via an epitope on ox-LDL (Tsimikas et al., 2000). PET 
and SPECT lack definition of anatomical structure and have limited spatial resolution, and 
therefore need to be combined with an imaging modality (CT or MRI), which can define 
anatomic structure.  
In terms of broad clinical applicability and availability, MRI is the most versatile technique. 
MRI does not involve ionizing radiation, has a high penetration depth, is safe and non-
invasive, suitable as a screening tool, which can be repeated at will and provides both 
anatomical and physiological information. Disadvantages of MRI are relatively long 
acquisition times and poor suitability for patients, who are claustrophobic. Molecular MRI 
of coronary artery plaque is difficult due to motion caused by respiration and cardiac 
contractions. These motions pose an upper limit to the time window of MRI signal 
acquisition during the cardiac cycle. However, development of more efficient pulse 
sequence protocols may reduce these problems in future. 
Molecular MRI employs contrast agent carriers to which antibodies, peptides or receptor 
(ant)agonists with affinity for the target of interest are conjugated (Mulder et al., 2007a). 
Larger carriers can harbor a higher payload of MR contrast generating Gd or iron oxides 
and can therefore have higher relaxivity. However, carriers which are very large may not 
enter the plaque due to the limited size of endothelial cell fenestrations. In atherosclerosis 
these fenestrations may exceed the regular size of 5 nm by far. In the apoE-/- mouse model 
neo-intimal thickening of the carotid artery induced by a constrictive collar could be 
visualized with paramagnetic liposomes which could pass the endothelial barrier despite a 
mean diameter of 90 nm (Mulder et al., 2006). In another study the effect of size of the 
contrast agent on plaque permeation was investigated (Van Bochove et al., 2011). This effect 
was tested in apoE-/- mice in which a tapered cast around the right carotid artery generated 
thin cap fibroatheromas and non-thin cap fibroatheromas as published previously (Cheng et 
al. 2006). Low molecular weight Gd-chelates (Gd-HP-DO3A) and micelles led to plaque 
enhancement which was highest with the longest retention in the non-thin cap 
fibroatheromas, whereas liposomes did not accumulate in any of the plaques (Van Bochove 
et al., 2011). These results implicate that targeted liposomes are most suitable for the 
imaging of plaque-associated endothelial markers, whereas micelles, which accumulate 
extravascularly on a long timescale, are suited for imaging of less abundant markers inside 
plaques. Low molecular weight compounds may be employed for target-specific imaging of 
highly abundant extravascular plaque-associated targets. 
4. Molecular MRI of atherosclerosis 
4.1 Extracellular matrix proteins 
The potential for in vivo molecular imaging of plaque collagen using a liposome 
functionalized with a collagen adhesion protein, CNA35, has been suggested after a series of 
in vitro tests (Sanders et al., 2009). Indirectly, quantification of collagen using this method 
could provide information about plaque phenotype, in particular plaque stability.  
Another extracellular matrix protein of plaque, which has potential for noninvasive 
assessment of plaque burden by molecular MRI in vivo is elastin. Changes in elastin content 
and the high abundance of elastin during plaque development make it a good quantitative 
marker of plaque burden, which was recently confirmed in a mouse model of 
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atherosclerosis with an elastin-specific MR contrast agent (Makowski et al., 2011). The 
strong MRI signal change provided by this agent allowed for imaging with high spatial 
resolution, not only resulting in accurate assessment of plaque burden, but also plaque 
characterization by quantification of intra-plaque elastin content using signal intensity 
measurements (Makowski et al., 2011).  
Gadofluorine M is an amphiphile with perfluorinated side chains, which forms micelles 
with a diameter of 5 to 6 nm in aqueous solution. Accumulation of Gadofluorine M micelles 
in atherosclerotic plaque has been attributed to the enhanced vessel-wall permeability and 
also to its affinity for both extracellular matrix proteins (Meding et al. 2007) and plaque 
lipids (Barkhausen et al., 2003).  
4.2 Cholesterol deposition 
Antibody-conjugated paramagnetic micelles have been used for targeted MRI of specific 
epitopes of ox-LDL in atherosclerotic plaque. At 72 and 96 hours after intravenous injection 
of ox-LDL-targeted micelles in apoE-/- mice, specific MRI signal enhancement of aortic 
plaque was observed. MRI signal enhancement was significantly lower after injection of 
control non-conjugated micelles and nonspecific IgG-conjugated micelles (Briley-Saebo et 
al., 2008). Despite this success in the preclinical setting, clinical application of the ox-LDL 
targeted micelles may be hampered by the long blood circulation times (>14 hours) and high 
liver uptake (20% of the injected dose). Cell apoptosis (Hak et al., 2009; Ide et al. 2005) and 
nephrogenic systemic fibrosis in patients with renal dysfunction (Pedersen, 2007) have been 
implied to be caused by gadolinium (Gd) released from paramagnetic MRI contrast agents. 
Therefore, excessive and prolonged retention of Gd-chelates in organs needs to be avoided.  
Ox-LDL in the plaque of apoE-/- mice has also been targeted with functionalized lipid-
coated ultra-small superparamagnetic iron particles (LUSPIOs) (<20 nm) (Briley-Saebo et al., 
2011). The aortic wall was enhanced on gradient echo images after injection in apoE-/- mice 
using a positive contrast method (GRASP). In contrast, no enhancement was observed after 
injection of control non-targeted LUSPIOs and larger (~40 nm) LSPIOs. In vivo specificity of 
the particles to ox-LDL increased after coating of the particles with lipids which prevented 
ingestion by macrophages.  
Another targeted imaging approach which features interaction with plaque cholesterol is the 
use of HDL-like particles. These particles have the advantages of being endogenous and 
biodegradable, do not trigger immune reactions and are not recognized by the RES 
(Cormode et al., 2008, 2009; Frias et al., 2006; Skajaa et al., 2010). Other attractive biological 
properties of HDL-like particles are that HDL enables reverse cholesterol transport from the 
plaque, has anti-atherothrombotic properties, and reduces oxidation and plaque 
inflammation (Skajaa et al., 2010). Various versions of HDL-mimicking nanoparticles have 
been designed for plaque imaging: reconstituted HDL-like spherical or discoid particles, 
fully synthetic HDL-like particles and fully synthetic nanocrystal HDL (Cormode et al., 
2009a; Skajaa et al., 2010). Spherical HDL-like particles were made up by apoA-I, extracted 
from human plasma, and reconstituted with commercially available phospholipids and Gd-
conjugated lipids (Frias et al., 2004). The signal intensity of the aortic wall of mice was 
highest at 24 hours after injection of the above particles and returned to baseline levels at 48 
hours after injection (Frias et al., 2004). Cheaper and easier manufacturing procedures 
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would facilitate the use of HDL-like particles. Two different methods of preparation of 
reconstituted HDL discs were compared for their in vivo efficacy of imaging aortic wall in 
apoE-/- mice (Frias et al., 2006). Both types of discs showed highest signal intensity of 
macrophage-rich plaques at 24 hours after injection, while advanced plaques containing 
more cholesterol crystals and less macrophages revealed most enhancement at 72 hours 
after injection (Frias et al., 2006). Two fully synthetic HDL-like disks based on two synthetic 
lipid-binding apo A-I mimicking peptides, 37pA and the cheaper and easier synthesized 
18A, were compared for their potential for in vivo MR enhancement. At 24 hours after 
injection both HDL disks provided similar plaque enhancement in the aorta of 
atherosclerotic mice (Cormode et al., 2008). In nanocrystal HDL the natural HDL core is 
replaced by inorganic nanocrystals while retaining the phospholipid coating. Via 
modification of both their core and their corona, these particles can be made suitable for 
multimodality imaging. In one study Gd-chelates were incorporated in the corona while the 
nanocrystal core was chosen to be based on gold for CT detection, quantum dots for optical 
imaging or iron oxide (FeO) for MRI visualization (Cormode et al., 2008). In vivo MRI 
showed positive enhancement of plaque when the core consisted of gold or quantum dot, 
whereas a significant decrease in signal was observed when the core contained FeO. 
Histology revealed at least partial colocalization with plaque macrophages (Cormode et al., 
2008). Additionally, all mentioned MRI-visible HDL-like nanoparticles might be useful to 
study the role of HDL in plaque progression (Skajaa et al., 2010).  
As mentioned earlier, Gadofluorine M is supposed to have affinity for plaque lipids 
(Barkhausen et al., 2003) and extracellular matrix proteins. In a rabbit model of 
atherosclerosis injection of Gadofluorine M led to a high contrast-to-background ratio on T1-
weighted MR images of aortic plaque (Barkhausen et al., 2003). The contrast-enhanced 
regions corresponded with Sudan-positive lipid-rich aortic wall segments on histological 
slices (Barkhausen et al., 2003). 
4.3 Endothelial cells 
Endothelial cells respond to several stimuli with increased expression of cell adhesion 
molecules. The inflammatory mediators, IL-1 and TNFǂ, are among these stimuli and lead 
to increased expression of ICAM-1, VCAM-1 and P-selectin by endothelial cells (Libby, 
2002). Oxidized low-density lipoproteins, accumulating in plaque during atherogenesis, 
represent a stimulus for enhanced expression of VCAM-1 by endothelial cells (Libby, 2002; 
Lusis, 2000; Ross, 1999). Leukocytes extravasate after interaction of VCAM-1 with very late 
antigen-4 (VLA-4) on the leukocyte membrane surface (Libby, 2002).  
The binding capacity of microparticles of iron oxide conjugated with antibodies directed 
against VCAM-1 (diameter ~4.5 µm) to TNFǂ-stimulated mouse endothelial cells was 
demonstrated in vitro (McAteer et al., 2010). These VCAM-1-targeted microparticles were 
applied for in vivo imaging of inflammation in peritubular capillaries in murine kidneys 
after ischemia reperfusion injury (Akhtar, 2010). VCAM-1 expression on dysfunctional 
endothelial cells of cholesterol-fed apoE-/- mouse aorta was targeted with a cross-linked 
iron oxide (CLIO) fluorescent nanoparticle conjugated to a peptide sequence with homology 
to the a-chain of VLA-4 for both MRI and fluorescence imaging (Kelly et al., 2005). Higher 
signal amplification of atherosclerotic mouse aorta was anticipated and found by this group 
using newly developed second-generation VCAM-1-targeted magnetic nanoparticles that 
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undergo internalization and trapping in endothelial cells and macrophages that express 
VCAM-1 (Nahrendorf et al., 2006). 
P-selectin expression by endothelial cells has been imaged with a slow-clearing blood-pool 
MRI contrast agent functionalized with sulfate groups with homology to the P-selectin 
binding region of P-selectin glycoprotein ligand-1 (Alsaid et al., 2009). Application of this P-
selectin-targeted paramagnetic agent led to specific plaque enhancement in apoE-/- mice 
between 10 and 30 minutes after intravenous injection. Ex vivo fluorescence microscopy 
confirmed specific binding of the agent to P-selectin (Alsaid et al., 2009). 
4.4 Neovascularization 
The reason for the development of neovasculature in atherosclerotic plaques is uncertain. 
One theory emphasizes the hypoxia in the thickened intimal layer (>500 µm) as a stimulant 
for neoangiogenesis (Sluimer & Daemen, 2009). Another theory however states that 
neovascularization may exist early on during atherogenesis and promotes plaque 
inflammation and progression by facilitating extravasation of inflammatory cells (Dunmore 
et al., 2007). Intraplaque hemorrhage of the fragile neovasculature has also been related to 
rapid carotid atherosclerotic plaque growth (Takaya et al., 2005). 
Dynamic contrast enhanced (DCE) MRI was applied first for quantitative assessment of 
neovasculature in tumors, but has been exploited more recently for quantification of human 
carotid plaque neovasculature (Yuan et al., 2002). DCE-MRI uses serial MRI acquisitions 
with high temporal resolution enclosing a time window around the injection of a low 
molecular weight Gd-containing contrast agent. Differentiation between fibrous tissue 
(enhancement ~80%) and lipid core (enhancement ~30%) by virtue of the neovessel density 
in fibrous tissue has been demonstrated (Yuan et al., 2002). Quantitative information on 
plaque uptake kinetics of contrast agent, amount of neovascularization and vessel 
permeability may be provided by appropriate modeling of the signal intensity time course 
in the plaque (Calcagno et al., 2010). 
Recently, Gadofluorine M uptake in the balloon-injured aorta of New Zealand White rabbits 
has been found to correlate with plaque neovessel and macrophage density (Sirol et al., 
2009). Histological evaluation showed that plaque neovessels, lipid-rich regions and 
Gadofluorine M co-localized. However, non-specificity of Gadofluorine M, which also has 
affinity for other plaque constituents like extracellular matrix proteins and lipids, will 
complicate mathematical modeling of quantitative parameters. 
Also targeted approaches have been used for the molecular MR imaging of plaque 
neovascularization. The ǂvǃ3 integrin is expressed amongst others by endothelial cells on 
angiogenic vessels in plaque. A low molecular weight peptidomimetic of Arg-Gly-Asp 
conjugated to Gd-DTPA led to enhancement of aortic plaque in apoE-/- mice which was 
diminished after “presaturation” with the MRI-silent, Europium-chelated analogue of the 
Gd-conjugated compound (Burtea et al., 2008).  
Targeting of proteins expressed on the outer endothelial cell membrane indicative for 
neovascularization has the distinct advantage that the contrast agent does not need to enter 
the plaque. This approach allows for the use of large, very potent, nanoparticulate MR 
contrast agents, like Gd-containing perfluorocarbon emulsion nanoparticles with a size of 
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about 250 nm (Anderson et al., 2000). Transgenic rats with a mutation in the leptin receptor 
represent a model for metabolic syndrome, resulting in abdominal obesity, atherosclerosis 
and myocardial lesions. The Gd-containing perfluorocarbon emulsion targeted towards the 
ǂvǃ3 integrin was used for imaging neovessels in aortic plaques of these rats (Cai et al., 
2010). Additionally, the effect of treatment with the anorectic and hypolipidemic drug 
benfluorex on plaque neovascularization was studied. Treated animals displayed an overall 
lower and patchy plaque enhancement in comparison to non-treated ones, indicative for a 
decreased angiogenic vessel density in the plaque (Cai et al., 2010). So, modulation of 
neovascularization by therapeutics could be studied using this molecular MRI approach. 
The same ǂvǃ3-targeted perfluorocarbon emulsion was used to monitor collateral formation 
after treatment with angiogenic L-arginine in a rabbit femoral artery ligation model (Winter 
et al., 2010). The results achieved in these diverse studies argue against a straightforward 
interpretation of MR imaging results in atherosclerosis using ǂvǃ3-targeted nanoparticles. 
Molecular MRI of neovascularization with these nanoparticles may not discriminate 
between adverse plaque neovascularization and beneficial sprouting of collaterals. At the 
time, pharmacokinetic profiling information on ǂvǃ3-targeted and non-targeted 
perfluorocarbon nanoparticles has been obtained in rabbits with in vivo MRI and blood 
samples (Neubauer et al., 2008). 
4.5 Macrophages 
Macrophages play a key role in the inflammatory process of atherosclerosis. Therefore, they 
are most extensively studied using molecular MRI. Previously, superparamagnetic particles 
of iron oxide were used for lymph node imaging in the context of tumor staging and 
detection of focal liver lesions (Schmitz, 2003). During a phase III trial which investigated 
the use of the ultra-small dextran-coated counterparts of these particles (USPIOs, diameter 
18-30 nm) for discrimination between healthy lymph nodes and lymph node metastases, 
these USPIOs were found by co-incidence to be ingested by aortic plaque macrophages 
(Schmitz et al., 2001). Since then these USPIOs have been extensively studied for their 
potential to monitor inflammation in atherosclerosis in patients and regression after 
treatment with aggressive lipid-lowering therapy (Tang et al., 2009).  
The versatility of these USPIOs for imaging of both lymph nodes and atherosclerotic plaque 
constitutes an important drawback of these USPIOs. Lymph nodes often develop in close 
proximity to the inflamed plaque lesion. We have shown that differentiation between peri-
vascular lymph nodes and aortic wall in atherosclerotic mouse models may be difficult 
using USPIOs (Te Boekhorst et al., 2010a). Successful visualization will depend on spatial 
resolution and the imaging sequence (Te Boekhorst et al., 2010a). Recently, a newly 
developed positive contrast technique for (U)SPIOs, “GRASP”, has been shown capable to 
differentiate between peri-vascular lymph nodes and atherosclerotic vessel wall (Briley-
Saebo et al., 2011).  
Apart from this cellular MRI approach, also specific macrophage membrane proteins have 
been targeted. Among others targeting of the macrophage scavenger receptor-A (MSR-A) 
has been achieved in a mouse model of atherosclerosis with paramagnetic Gd-containing 
micelles (Amirbekian et al., 2007). Plaques in the aortic wall of apoE-/- mice displayed a 
79% increase in signal intensity upon injection of the MSR-A-targeted micelles, whereas 
control micelles resulted in 34% signal increase (Amirbekian et al., 2007). MSR-A together 
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with MSR-B is responsible for 75-90% of ox-LDL uptake by macrophages. Ex vivo targeting 
of MSR-B in dissected human aortic atherosclerotic plaque has been achieved with 125-nm-
diameter lipid-based nanoparticles (Lipinski et al., 2009). However, the potential of these 
MSR-B-targeted nanoparticles for in vivo targeting has still to be demonstrated. Bimodal 
micelles for MSR (A and B) containing both Gd and an optical label (rhodamine-conjugated 
lipid or a quantum dot) led to a signal increase of aortic wall in apoE-/- up to 200% (Mulder 
et al., 2007b). MSR-targeted rhodamine micelles could be detected with fluorescence 
microscopy and were found to be associated with macrophages. Quantum dots allowed ex 
vivo detection of aortic macrophage-rich regions with UV illumination (Mulder et al., 2007b).  
Plaque macrophages express the ox-LDL receptor LOX-1 and binding of ox-LDL induces 
apoptosis, expression of adhesion molecules and release of MMPs (Ross, 1999; Li et al., 
2010). Paramagnetic liposomes conjugated to anti-LOX-1 antibodies were injected in 
LDL-R-/- mice. Aortic plaques were specifically enhanced on T1 weighted MR images, 
while no enhancement was observed on MR images from double knockout LDL-R-/- 
LOX-1-/- mice or from LDL-R-/- mice injected with nonspecific IgG-conjugated liposomes 
(Li et al., 2010). Histological analyses revealed that most LOX-1 co-localized with 
macrophages, apoptotic cells and MMP-9 and only a small proportion with proliferated 
smooth muscle cells.  
The use of antibodies for making contrast agents target specific has important 
disadvantages: the high costs of antibodies, their immunogenicity and difficulty in handling 
and preparation. Application of other specific targeting moieties of non-antibody origin is 
therefore attractive. An example is the use of phosphatidylserine (PS) incorporated in self-
assembled lipid-based contrast agents. PS is expressed on apoptotic cells and is specifically 
recognized by macrophages. PS-containing paramagnetic liposomes showed in vitro 
specificity for RAW cells (mouse macrophages) and significant MR enhancement of aortic 
plaques during the first 4 hours after injection in apoE-/- mice (Maiseyeu et al., 2009). 
Another targeted approach avoiding the use of antibodies employs a potent synthetic 
agonist (HU-308) of the peripheral cannabinoid receptor (CB2-R) (Te Boekhorst et al., 
2010b). T-lymphocytes and macrophages in advanced mouse and human atherosclerotic 
plaque CB2-R have been shown to express this CB2-R (Steffens et al., 2005). Activation of 
CB2-R by HU-308 results in amelioration of plaque phenotype in atherosclerotic mice 
(Steffens et al., 2005). The suggested mechanism is an immune system modulating effect 
through CB2-R, which involves a regulatory negative feedback effect dampening the 
inflammatory process in advanced plaques (Steffens et al., 2005). Self-assembly of polymeric 
micelles was easily achieved by mixing HU-308, which has a 7-carbon tail and a hydrophilic 
head group, with Gd-containing and PEG-ylated lipids (Te Boekhorst et al., 2010b). T1-
weighted inversion recovery fast spin echo MR images revealed in vivo plaque enhancement 
in the aortas of double knockout apoE-/-, eNOS-/- mice between 36 and 48 hours after 
injection of CB2-R-targeted micelles (Te Boekhorst et al., 2010c).  
The earlier mentioned flexible HDL platform could be easily functionalized for more specific 
retention into plaques. A third example of targeted approach avoiding the application of 
antibodies concerns incorporation of an apoE-derived lipopeptide into HDL particles 
enriched with Gd-based lipids (W. Chen et al., 2008). Application of this material led to both 
higher association with mouse macrophages in vitro and more pronounced in vivo 
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enhancement of aortic plaque in mice relative to reconstituted HDL without incorporation 
of the apoE-derived lipopeptide (W. Chen et al., 2008). 
Furthermore, hyaluronic acid, which targets the CD44 receptor on activated macrophages, 
has been conjugated to a lipid coating enclosing iron oxide nanoparticles (Kamat et al., 
2010). In vitro experiments have revealed ingestion by activated THP-1 macrophages, 
suggesting potential for in vivo imaging of plaque inflammation (Kamat et al., 2010). 
Transient cellular location of the HDL particles was suggested by a series of Prussian blue 
stainings for iron. Despite these promising findings, the in vivo potential of these 
macrophage-targeted iron oxides for MRI of plaque inflammation has still to be confirmed. 
Apart from direct targeting of macrophages, one can also address released macrophage 
products. An example of an extracellular released enzyme in atherosclerotic plaque is 
represented by the matrix metalloproteinases (MMPs). Increased activity of MMPs 
produced by smooth muscle cells and macrophages has been reported to be related to 
plaque rupture (Vink & Pasterkamp, 2002; Schafers et al., 2010). A small peptide with 
affinity for MMPs was conjugated to Gd-DOTA and employed for in vivo MR imaging of 
plaque (Lancelot et al., 2008). The plasma half-life of this small peptide was only 30 minutes 
and the concentrations in artery specimens were 3 times as high as those after injection of 
Gd-DOTA, with prolonged retention at least until 22 hours after injection (Lancelot et al., 
2008). The mentioned peptide has affinity for various MMPs. However, the MMP family is 
large and the role of each MMP member is not entirely known. It has been shown, that 
expression of MMP-2 and MMP-9 is upregulated in shoulder regions of human vulnerable 
plaques (Galis & Khatri, 2002). The advent of specific inhibitors of MMP-9 and -2 and their 
application in small paramagnetic peptides may improve specificity for unstable plaque.  
Another protein that has been linked to adverse cardiovascular events in patients after 
carotid endarterectomy surgery is neutrophil gelatinase-associated lipocalin-2 (NGAL) (Te 
Boekhorst et al., 2011). NGAL is produced and released particularly by macrophages, 
although first discovered in neutrophils (Hemdahl et al., 2006). MMP-9 activity is prolonged 
and degradation prevented after binding to NGAL. Apart from forming a stable and 
biologically active complex with MMP-9, NGAL mediates inflammatory activity through 
binding to formyl-methionyl-leucyl-phenylalanine (fMLP; a chemotactic peptide), 
leukotriene B4, and platelet-activating factor (Hemdahl et al., 2006). In vivo MRI of severely 
advanced atherosclerotic plaques of the double knockout apoE-/-, eNOS-/- mouse was 
performed at 24 and 72 hours after injection of 24p3(mouse homologue of NGAL)-targeted 
micelles and IgG isotype antibody-conjugated micelles (Te Boekhorst et al., 2011). Both 
24p3-targeted and control micelles led to an increased average Normalized Enhancement 
Ratio (NER) at 24 hours after injection (~1.45 versus ~1.30 respectively), while at 72 hours 
after injection of 24p3-targeted micelles average NER further increased and after injection of 
control micelles average NER had decreased (~1.70 versus ~1.20) (Te Boekhorst et al., 2011). 
Histology revealed that micelles co-localized with 24p3 and partially with macrophages. 
The results of this study are summarized in Figure 1A-H. 
Targeting of extracellular located molecules such as MMPs and NGAL has the advantage 
over intracellular targets that the target is readily available. On the other hand, it may carry 
the drawback that the contrast agent is easily washed out from the plaque, together with the 
target, into the blood. Nevertheless, imaging of intact excreted proteins and particularly 
their activity could provide important insights in the inflammatory state of the plaque. For   
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Fig. 1. MR images and histological stainings of atherosclerotic plaque after intravenous 
injection of NGAL/24p3-targeted micelles. Pre- and post-injection (0, 24 and 72 h) MR 
images of aortic wall in apoE-/-/eNOS-/- mice injected with control (A-C) and NGAL/24p3-
targeted (E-G) micelles and immunohistochemistry at 72 hours for micelle-conjugated rat 
antibodies in control micelles (D) and NGAL/24p3-targeted micelles (H). P=plaque, 
LN=lymph node. NER= Normalized Enhancement Ratio. The post-injection MR images 
show increased signal intensity at 24 hours for both NGAL/24p3-targeted micelles and 
control micelles, while signal intensity at 72 hours stays at the higher level for NGAL/24p3-
targeted micelles but returned to baseline for control micelles. Note that the signal intensity 
of the peri-aortic lymph node, which was removed during harvesting of the aorta, is also 
increased after injection. Histology of the mouse aorta at 72 hours after injection revealed no 
staining of micelles for injections with control micelles and extensive red staining for 
injections with NGAL/24p3-targeted micelles.. H: scale bar = 100µm (original magnification: 
100x) (Te Boekhorst et al., 2011). 
example, peroxidase-based hematologic profiling has been shown to predict adverse cardiac 
events during a follow-up of 1 year (Brennan et al., 2010). In order to prevent washout of the 
agent, Bogdanov and coworkers have designed an activatable (smart) low-molecular weight 
Gd-containing probe for imaging of myeloperoxidase, an enzyme released by macrophages 
that is responsible for oxidation of LDL via the formation of reactive oxygen species (J.W. 
Chen et al., 2004). Activation of the probe by myeloperoxidase leads to polymerization, 
increasing its size and relaxivity, and prolonging its retention in the target region – hence 
providing an indirect readout of enzyme activity. This probe enabled MR imaging of 
increased myeloperoxidase activity in plaques in the aorta of rabbits, as is summarized in 
Figure 2A-G (Ronald et al., 2009). 
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Fig. 2. Imaging of diseased aortas of cholesterol-fed rabbits before and after injection of an 
activatable MPO sensor.  
Imaging before and 2 hours after injection of DTPA-Gd (A,D), before and 2 hours after 
injection of bis-tyr-DTPA-Gd (B,E) which is a nonactivatable analog of MPO-Gd, and before 
and 2 hours after injection of the functional agent MPO-Gd (C,F). Histology of the rabbit 
aorta after injection of MPO-Gd revealed focal MPO presence in the plaque and confirmed 
the MR findings (G). Printed with permission from (Ronald et al., 2009).  
4.6 Apoptotic cells 
When cells become apoptotic, phosphatidylserine (PS), initially mainly found in the inner 
leaflet of the viable cell membrane, is also expressed on the outer leaflet of the cell. The 
expression of PS can be detected with molecular MRI using the protein annexin A5 as a 
targeting ligand. Annexin A5 binds specifically to PS in the presence of calcium (Gerke et al., 
2002). Apoptosis in atherosclerotic plaques in the aorta of apoE-/- mice was studied using 
Gd-containing micelles conjugated to annexin A5. T1-weighted MR images showed at 24 
hours after injection a slight, but significant, increase of plaque intensity relative to control 
non-conjugated micelles (Van Tilborg et al., 2010).  
Phage display may identify small peptides with specific affinity to selected targets. One 
study employed a PS-specific peptide, identified by phage display and conjugated to 
Gd-DTPA, for detection of apoptotic cells in aortic plaques of apoE-/- mice at 30 minutes 
after injection (Burtea et al., 2009). The use of such small peptides has certain advantages 
above proteins or antibodies in terms of reduced immunogenicity and a cheaper and easier 
production process.  
However, studies with apoptosis-directed agents in a number of apoptosis-associated 
pathologies have also revealed the limitation of apoptosis-targeted contrast agents. The 
publication of a SPECT study reporting visualization of apoptosis of cardiomyocytes in 
patients with acute myocardial infarction (Hofstra et al., 2000) may serve as an example. 
Apoptosis may not be useful for targeted imaging of vulnerable plaque in the coronary 
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arteries, due to the possibly overwhelming background signal of enhanced cardiac muscle 
in a compromised patient group. 
4.7 Activated platelets and thrombus 
Activated platelets play a crucial role in the formation of repetitive micro-thrombi, which 
suddenly may result in a major thrombus, followed by an acute cardiovascular event 
(Naghavi et al., 2003a, 2003b; Stary et al., 1995). Therefore, early recognition of a high 
incidence of micro-thrombi by molecular imaging of activated platelets has important 
prognostic value.  
Activated platelets express ǂIIbǃ3 integrin, which has been targeted with cyclic arginine–
glycine–aspartic acid (RGD) peptides, which are specific for the ǂIIǃ3 integrin among 
others, and are conjugated to ultra-small particles of iron oxide for T2* weighted MRI 
(Johansson et al., 2001). Unfortunately, the resolution, which was achieved with RGD-
USPIO-enhanced MRI, was too low to detect thrombus in vivo (Johansson et al., 2001). 
Chemical conjugation to nanoparticles typically results in the loss of antibody functionality. 
A biochemically robust, highly reproducible and site-specific coupling method using the 
Staphylococcus aureus sortase A enzyme for the conjugation of single-chain antibodies 
(scFv) to amine-coated superparamagnetic iron oxide nanoparticles was developed (Ta et 
al., 2011). Conjugation efficiency ranged between 50 and 70% and the bioactivity of the scFv 
with specific affinity to activated platelets was preserved after conjugation. In vivo MRI 
showed that these scFv-conjugated SPIOs effectively bound to activated platelets on FeCl3 
induced thrombus in carotid arteries of mice (Ta et al., 2011). 
Fibrin-targeted small peptides conjugated to Gd-DTPA have been employed successfully in 
pigs, showing the feasibility of MRI to differentiate between acute and subacute (1-3 days 
old) coronary thrombus (Botnar, 2004a, 2004b). More recently, MR enhancement of 
thrombus has been achieved in a phase II trial using these peptides in patients, with a 
diagnosed symptomatic thrombus in vessel territories potentially associated with stroke 
(Spuentrup et al., 2008). 
Gd-perfluorocarbon nanoparticles functionalized with fibrin-targeted peptides were also 
applied for MR imaging of in vitro human thrombus (Winter et al., 2003). These 
perfluorocarbon nanoparticles can be used for T1-weighted proton MRI as well as for 19F 
hot-spot MR imaging. The advantage of the latter feature is the natural absence of 
background signal precluding the necessity of a baseline scan, which is attractive for clinical 
application from a logistical point of view.  
Also contrast agents based on the paramagnetic chemical exchange saturation transfer 
(PARACEST) mechanism have been employed for MR imaging of fibrin. This technique has 
been pioneered by the group of Balaban et al. (Ward et al., 2000). PARACEST agents have 
exchangeable protons (–NH, –OH, etc.) that resonate at a chemical shift position that is 
distinguishable from the bulk water signal. When an RF pulse is applied at the resonance 
frequency of the exchangeable protons, these protons will be saturated. Transfer into the 
bulk water pool will lead to reduced equilibrium magnetization. This so-called saturation 
transfer effect can be switched ‘‘on’’ and ‘‘off’’ by simply changing the pulse sequence. The 
PARACEST agents are potentially attractive for in vivo use, because contrast can be switched 
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on and off by selective RF pulse saturation, avoiding the need for baseline imaging and 
spatial registration of images acquired hours or days apart. The main disadvantage of 
PARACEST agents, however, is low sensitivity, which hampers the ability to image 
molecular targets. One method of increasing the sensitivity of paraCEST agents is to 
incorporate multiple metal chelates into a macromolecular scaffold. Proof of concept CEST 
imaging of fibrin was provided in vitro for fibrin clots, using a fibrin-specific 
perfluorocarbon nanoparticle containing multiple PARACEST units (Winter et al., 2006). 
This first generation PARACEST nanoparticle agent, however, introduced a large cationic 
charge on the particle surface. Cationic particles can cause significant in vivo toxicity and 
are not suitable for biomedical applications. In a recent study, a neutral lipid conjugated 
PARACEST chelate was incorporated onto the surface of PFC nanoparticles leading to a 
negative surface charge. PARACEST and 19F MRI showed a linear increase in both 
PARACEST contrast to noise ratio and the 19F signal with increasing nanoparticle 
concentration. Artificial fibrin clots were efficiently targeted using these nanoparticles and 
imaged using PARACEST and 19F MRI (see Figure 3) with detection limits of 2.30 nM and 
4.60 nM respectively (Cai et al., 2011).  
 
 
 
Fig. 3. Dual PARACEST and 19F MR imaging of a clot treated with fibrin-targeted 
PARACEST nanoparticles.  
PARACEST contrast to noise ratio map (A) and 19F image (B) collaboratively show 
nanoparticles bound to the surface of the clot. The grayscale color bar represents the 
PARACEST CNR depicted in (A). (C) The nanoparticle concentration (nM) is color-coded 
and overlaid onto the PARACEST subtraction image to demonstrate colocalization of these 
two definitive signals. Printed with permission from (Cai et al., 2011). 
Various products of the coagulation cascade may serve as targets for molecular MRI as well. 
Very recently, a thrombin inhibitor was conjugated to perfluorocarbon nanoparticles for 
localized in vivo control of thrombus in the common carotid artery of a mouse after acute 
photochemical injury (Myerson et al., 2011). The modified nanoparticles outperformed heparin 
and the free thrombin inhibitor according to the activated partial thromboplastin time. 
The earlier mentioned fibrin-targeted small-peptide MR contrast agents have low sensitivity 
for the estimation of thrombus age. Specific targeting of earlier phases of thrombus 
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formation could help into this respect. Activated factor XIII cross-links fibrin chains and 
covalently cross-links ǂ2-antiplasmin to fibrin, with a rapid decline in catalytic activity. 
Therefore, the potential of an ǂ2-antiplasmin-based peptide labeled with rhodamine and Gd 
for specific detection of early thrombus was investigated both in vitro and in vivo (Miserus et 
al., 2009). Thrombus was induced via application of FeCl3 to the carotid artery of mice. In 
one group the contrast agent was injected seconds after thrombus formation, while in 
another group injection was postponed 24 to 48 hours after thrombus formation. Only early 
thrombus was enhanced using this contrast agent while thrombus with an age of 24 -48 
hours was not enhanced (Miserus et al., 2009). 
5. View-to-future 
As described above, MRI is capable of providing detailed cellular and molecular imaging 
information, which combined with the wealth of anatomical and functional MRI readouts, 
makes MR imaging of atherosclerosis a very powerful asset to study plaque vulnerability, 
progression and to evaluate effects of treatment. A potential limitation of MRI, however, is 
the limited sensitivity of the technique in the detection of low concentrations of targeted 
contrast agent.  
Development of improved MR techniques may enhance the sensitivity of detection. 
Hyperpolarization of nuclear spins through dynamic nuclear polarization (DNP) has 
recently attracted considerable attention for increasing the signal-to-noise ratio in an NMR 
experiment by several orders of magnitude (Ragavan et al., 2011). However, application of 
this technique to larger molecules has so far proven challenging. Recently, a full length 
protein was hyperpolarized at low temperature and dissolved for NMR signal acquisition in 
the liquid state in mixtures of organic solvent and water. Signal enhancements of 300-2000 
are obtained in partially deuterated polypeptide when hyperpolarized on 13C and of 30-180 
when hyperpolarized on 1H (Ragavan et al., 2011). Additionally, low-field (1 T) compact 
benchtop MRI systems (ASPECT, IconBruker) are ideally suited to take advantage of the 
higher relaxivity of Gd-based contrast agents at low magnetic fields.  
Although MRI-based single cell detection with the use of iron oxides has been reported, in 
general, much higher doses are needed as compared to for example the nuclear imaging 
techniques (Leuschner et al., 2011). Moreover the effect of covalent binding of 
peptides/lipids to Gd on the pharmacokinetics and biodistribution of the various contrast 
agent ingredients is uncertain. This complicates rapid approval of Gd-based MR contrast 
agents and its carriers for human application by the Food and Drug Administration (FDA 
(USA)) and European Medicines Agency (EMEA (Europe)), because of the concerns about 
retention in the body and toxicity. Issues are, amongst others, the unknown metabolic fate of 
the carrier material in the body, transmetallation of Gd3+ with native metal-ions in the 
body (Hak et al., 2009), and worries about Gd-induced nephrogenic systemic fibrosis 
(Pedersen, 2007). In this respect, nanocrystal HDL-like particles with iron oxide cores 
(Cormode et al., 2008; Mulder Acc Chem Res 2009; Skajaa et al., 2011) are very promising 
MR contrast agent candidates for clinical application because they seem to avoid most of 
these toxicity concerns. Figure 4 shows a schematic depiction of a nanocrystal HDL-like 
nanoparticle and summarizes some results achieved with it (Skajaa et al., 2011). 
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Fig. 4. Nanocrystal HDL with FeO core. Schematic depiction of FeO-HDL (a). (b) In vivo T2*-
weighted (TR = 10 ms, TE = 4 ms) MR image of abdominal region of an apoE-/- mouse, 24 h 
post-injection of FeO-HDL. The white arrow denotes the black rim (black spot) in the aortic 
wall observed after FeO-HDL administration. (A, aorta, V, inferior cava vein). (c) Ex vivo 
confocal laser microscopy of excised aorta section. Nuclei are shown in blue via DAPI 
staining, FeO-HDL in red (rhodamine), green color marks macrophages, stained with Alexa 
647-CD68 and yellow marks co-localization of FeO-HDL and macrophages. (d) In vitro TEM 
images of FeO-HDL in buffer. (e) In vitro negative staining TEM image of FeO-HDL, 
showing that each iron oxide (IO) particle is coated with a single monolayer of 
phospholipids. (f, g) TEM and negative staining TEM of blood samples 5 min after the 
administration of FeO-HDL revealed individually dispersed particles, i.e. no aggregation 
and that the lipid coating is intact. Printed with permission from (Skajaa et al., 2011). 
The use of frequency-selective paraCEST agents or perfluorocarbon nanoparticles in 
principle permits imaging of various target species simultaneously. Although in vitro proof 
of principle has been provided, in vivo application has been limited so far. Problems for 
paraCEST agents are related to low sensitivity and susceptibility artifacts, whereas 19F 
imaging also suffers from relatively low sensitivity. Concerning clinical translation, the iron 
oxides are most promising, since they enable the most sensitive detection with MRI while 
toxicity is low. The larger iron oxides provide sensitive hypointense contrast on T2-weighted 
images, whereas small iron oxides (~5 nm) can also be used for T1-weighted imaging with 
hyperintense contrast (Taboada et al., 2007). 
The application of both diagnostic and therapeutic MR agents for monitoring of drug 
delivery and therapeutic responses is very promising. Gd-containing liposome-encapsulated 
prednisolone phosphate was injected in atherosclerotic rabbits and delivery at the balloon-
injured aorta was imaged with MRI (Lobatto et al., 2010). The therapeutic anti-inflammatory 
and anti-angiogenic effects of the glucocorticoid were monitored with DCE MRI (Lobatto et 
al., 2010). Another study employed paramagnetic ǂνǃ3-targeted fumagillin-loaded 
perfluorocarbon nanoparticles, releasing fumagillin via “contact facilitated drug delivery” 
(only upon ligand-directed binding) (Winter et al., 2006). These nanoparticles resulted after 
1 week in a significant reduction in degree and spatial distribution of MR enhancement. This 
effect was not observed when no drug or non-targeted fumagillin-loaded nanoparticles 
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were administered (Winter et al., 2006), thus providing evidence for the specific therapeutic 
effect of the targeted, drug-loaded nanoparticles. 
6. Clinical application 
In patient studies iron oxide particles and Gadofluorine M have already been successfully 
applied for MRI of inflammation. The use of MRI with these particles combined with MRI 
assessment of cardiovascular function and myocardial tagging in selected patient 
populations with specific co-morbidity that increases risk for atherosclerotic disease may 
further stratify cardiovascular risk groups. Clinical application of self-assembling Gd-based 
molecular contrast agents is difficult due to the large amounts needed for detection and 
toxicity issues, especially in patients with kidney disease. Molecular targeted iron oxide 
nanoparticles conjugated to small peptides, recognized by phage display have lower 
immunogenicity when compared to full antibodies but toxicity may still hamper clinical 
application. Into this respect, the use of synthetic (ant)agonists or peptidomimetics for 
conjugation to MR visible nanoparticles combined with MRI of plaque targets in selected 
patient groups is anticipated to be more successful. Clinical application of perfluorocarbon 
nanoparticles for imaging of intravascular targets (endothelial cell markers and 
thrombus/activated platelets) employing the zero-background 19F signal is attractive. The 
safety of fluorine and the high payload of 19F which counterbalances low sensitivity of 19F 
MRI, make these perfluorocarbon nanoparticles (without Gd) useful contrast agents with 
clinical potential for targeted imaging of intravascular targets. However, first the 
pharmokinetic profiling information obtained in rabbits (Neubauer et al., 2008) needs to be 
expanded and should be obtained in patients. Activatable Gd- or iron oxide-based contrast 
agents sensing plaque enzyme activity may be used for detection of enzymes available at 
nM concentrations owing to enhanced relaxivity related to oligomerization of substrates or 
coupling of them to proteins (Tu et al., 2011). This approach is interesting in the scope of 
clinical application because it measures activity instead of presence of enzymes and lower 
toxicity is anticipated because lower Gd (or iron oxide) concentrations are needed for a 
certain degree of enhancement. The endogenous nature of the lipid coat of FeO-HDL-like 
nanoparticles, the easy incorporation of natural or synthetic lipids for increased 
accumulation in plaque macrophages, and the low toxicity of FeO makes these nanoparticles 
an attractive contrast agent for clinical MRI of atherosclerotic plaque. Clinical application of 
a specific molecular MRI method will also depend on costs of the contrast agent for a 
specific target of interest, the versatility of that agent and the contribution of this MRI 
approach to clinical decision making.  
7. Conclusion 
A number of strategies for cellular and molecular MRI of atherosclerosis were successfully 
developed. Proof of concept clinical application was already established for imaging of 
macrophages using non-targeted iron oxides and at a more immature stage for the 
fibrin-targeted small-molecule peptides conjugated to Gd-DTPA. Future studies will have to 
clarify whether the targeted contrast agents have diagnostic or prognostic added value in 
the evaluation of atherosclerotic plaque progression/rupture in humans. Promising new 
developments include activatable contrast agents, which are able to report on enzyme 
activity, perfluorocarbon nanoparticles exploiting the zero-background 19F signal, as well as 
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the use of modified MRI-visible endogenous nanoparticles, such as HDL and LDL, for 
imaging of atherosclerosis and specific plaque components. 
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